K2M adds two additions to family of ALEUTIAN Interbody Systems for lumbar applications

NewsGuard 100/100 Score

K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today debuted two additions to the family of ALEUTIAN® Interbody Systems at the 2011 North American Spine Society (NASS) Annual Meeting in Chicago.

“K2M's debut of two new next generation products in the ALEUTIAN family of products demonstrates our dedication to developing and improving upon our rapidly growing portfolio”

Furthering the company's commitment to continue to enhance its extensive product portfolio, the ALEUTIAN Transforaminal-Lumbar (TLIF) II Interbody System features a full range of unique bulleted PEEK interbodies for posterior lumbar applications. The ALEUTIAN TILF II will include the Adjustable Inserter, which allows for variable angulation of the implant from 0° to 55° in-situ, helping the surgeon to insert the TLIF interbody with precision and ease. For oblique implant placement through a transforaminal-lumbar approach, the ALEUTIAN Anatomically-Narrow (AN) Oblique Interbody System offers innovative instrumentation that helps facilitate more efficient intraoperative use of the system.

"The bulleted nose of the ALEUTIAN TLIF II implant simplifies interbody insertion and the open-structure design provides a substantial amount of room for graft material. The implant features, combined with state-of-the-art instrument technology, makes the ALEUTIAN TLIF II Interbody System a great choice for my patients who require a transforaminal interbody fusion," stated Dr. George Miz, Orthopedic Surgeon at Bone and Joint Physicians.

The clinical application of the ALEUTIAN Transforaminal-Lumbar II Interbody System will be shown in a Hands-On Demonstration at NASS, today from 10:00 - 10:30 am Central (K2M Booth #1616).

"K2M's debut of two new next generation products in the ALEUTIAN family of products demonstrates our dedication to developing and improving upon our rapidly growing portfolio," stated Eric Major, K2M's President and CEO. "Given the significant expansion of our global distribution team and the number of new and existing customers in need of high quality interbody systems, it is critical that we continue to introduce new technologies."

Source:

K2M, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stem cell therapy safe and potentially beneficial for spinal cord injury patients